JP2013513606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513606A5 JP2013513606A5 JP2012543111A JP2012543111A JP2013513606A5 JP 2013513606 A5 JP2013513606 A5 JP 2013513606A5 JP 2012543111 A JP2012543111 A JP 2012543111A JP 2012543111 A JP2012543111 A JP 2012543111A JP 2013513606 A5 JP2013513606 A5 JP 2013513606A5
- Authority
- JP
- Japan
- Prior art keywords
- retinal
- disease
- acute
- optic
- macular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 description 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 208000029977 White Dot Syndromes Diseases 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000004849 posterior scleritis Diseases 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26789709P | 2009-12-09 | 2009-12-09 | |
| US61/267,897 | 2009-12-09 | ||
| PCT/US2010/055590 WO2011071620A1 (en) | 2009-12-09 | 2010-11-05 | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016005576A Division JP2016056207A (ja) | 2009-12-09 | 2016-01-14 | プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013513606A JP2013513606A (ja) | 2013-04-22 |
| JP2013513606A5 true JP2013513606A5 (https=) | 2015-07-09 |
| JP5955774B2 JP5955774B2 (ja) | 2016-07-20 |
Family
ID=43503864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543111A Expired - Fee Related JP5955774B2 (ja) | 2009-12-09 | 2010-11-05 | プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法 |
| JP2016005576A Pending JP2016056207A (ja) | 2009-12-09 | 2016-01-14 | プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016005576A Pending JP2016056207A (ja) | 2009-12-09 | 2016-01-14 | プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20110136872A1 (https=) |
| EP (1) | EP2509582A1 (https=) |
| JP (2) | JP5955774B2 (https=) |
| KR (1) | KR20120106788A (https=) |
| CN (1) | CN102762195B (https=) |
| AR (1) | AR078929A1 (https=) |
| AU (1) | AU2010328555B2 (https=) |
| CA (1) | CA2783707A1 (https=) |
| CL (1) | CL2012001545A1 (https=) |
| IL (1) | IL220240A0 (https=) |
| MX (1) | MX2012006622A (https=) |
| NZ (1) | NZ600577A (https=) |
| RU (1) | RU2012127869A (https=) |
| SG (1) | SG181600A1 (https=) |
| TW (1) | TW201138766A (https=) |
| WO (1) | WO2011071620A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2711425T3 (es) | 2012-08-27 | 2019-05-03 | Allergan Inc | Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos |
| KR101535825B1 (ko) | 2012-09-25 | 2015-07-10 | 엘지디스플레이 주식회사 | 표시장치 및 이의 라인결함 검출방법 |
| JP6626831B2 (ja) * | 2014-02-20 | 2019-12-25 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少 |
| ES2757798T3 (es) | 2014-10-02 | 2020-04-30 | Allergan Inc | Profármacos de éster de gamma-lactamas y su uso |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2021316C (en) * | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5028624A (en) * | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| JP2002521332A (ja) * | 1998-07-21 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼薬組成物 |
| DK1321144T3 (da) * | 2000-09-13 | 2011-03-07 | Santen Pharmaceutical Co Ltd | Øjendråber |
| EP1532981B1 (en) * | 2002-08-23 | 2007-09-26 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
| SI1759702T1 (sl) * | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina |
| US20050276867A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
| EP1856042B1 (en) * | 2005-03-10 | 2012-06-27 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| WO2008096804A1 (ja) * | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
| UA103616C2 (ru) * | 2008-04-24 | 2013-11-11 | Аллерган, Инк. | Замещенные гамма-лактамы как терапевтические агенты |
| EP2127638A1 (en) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
-
2010
- 2010-11-04 US US12/939,861 patent/US20110136872A1/en not_active Abandoned
- 2010-11-05 EP EP10782082A patent/EP2509582A1/en not_active Withdrawn
- 2010-11-05 KR KR1020127017676A patent/KR20120106788A/ko not_active Ceased
- 2010-11-05 TW TW099138227A patent/TW201138766A/zh unknown
- 2010-11-05 RU RU2012127869/15A patent/RU2012127869A/ru not_active Application Discontinuation
- 2010-11-05 WO PCT/US2010/055590 patent/WO2011071620A1/en not_active Ceased
- 2010-11-05 JP JP2012543111A patent/JP5955774B2/ja not_active Expired - Fee Related
- 2010-11-05 CA CA2783707A patent/CA2783707A1/en not_active Abandoned
- 2010-11-05 AR ARP100104122A patent/AR078929A1/es unknown
- 2010-11-05 AU AU2010328555A patent/AU2010328555B2/en not_active Ceased
- 2010-11-05 CN CN201080063225.1A patent/CN102762195B/zh not_active Expired - Fee Related
- 2010-11-05 SG SG2012042461A patent/SG181600A1/en unknown
- 2010-11-05 NZ NZ600577A patent/NZ600577A/en not_active IP Right Cessation
- 2010-11-05 MX MX2012006622A patent/MX2012006622A/es not_active Application Discontinuation
-
2012
- 2012-06-07 IL IL220240A patent/IL220240A0/en unknown
- 2012-06-08 CL CL2012001545A patent/CL2012001545A1/es unknown
-
2015
- 2015-08-26 US US14/836,785 patent/US20160220677A1/en not_active Abandoned
-
2016
- 2016-01-14 JP JP2016005576A patent/JP2016056207A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008111497A1 (ja) | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 | |
| RU2009145939A (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| JP2012525415A5 (https=) | ||
| JP2015134824A5 (https=) | ||
| WO2012047966A3 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2017515811A5 (https=) | ||
| JP2017514917A5 (https=) | ||
| WO2013030679A3 (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
| JP2012505162A5 (https=) | ||
| EP4477233A3 (en) | A stable liquid formulation of fusion protein with igg fc domain | |
| JP2010536797A5 (https=) | ||
| JP2014533274A5 (https=) | ||
| JP2019524826A5 (https=) | ||
| JP2013513606A5 (https=) | ||
| PH12020551015A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| HRP20220138T1 (hr) | Peptidni pripravci i postupci uporabe | |
| WO2018022437A8 (en) | MULTIKINASE INHIBITORS AND THEIR USES IN OCULAR FIBROSIS | |
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| WO2020099925A3 (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| CN110072849A (zh) | 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 | |
| MX2013001870A (es) | Formulaciones oftalmicas de escualamina. | |
| JP2024506384A5 (https=) | ||
| WO2013184650A3 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| JP2018508528A5 (https=) |